Key contacts

Peter Molloy

Peter Molloy
Founding Director

Simon Bindloss

Simon Bindloss
Business Development Manager

Regional office - North America
295 Madison Avenue
18th Floor, New York
NY10017 United States

Tel: +1 646 653 7026
enquires@edisongroup.com

listed companies

Sunesis Pharmaceuticals GW Pharmaceuticals
TransAtlantic Petroleum Afferro Mining
South American Silver Corp Infinity Pharmaceuticals
Exelixis Idenix
Pharmacyclics Ariad Pharmaceuticals
Arrowhead Research Corporation AVEO Pharmaceuticals
Sangamo BioSciences TransDigm Group
Array BioPharma Alnylam Pharmaceuticals
Spirit AeroSystems FLIR Systems
BioCryst Pharmaceuticals BioLineRx
See more

Companies with HQs in usa

Investment Companies Photocure
Caledonia Mining Veris Gold Corp
Nordgold Ardea Biosciences
CAE Woulfe Mining
RGI International Altius Minerals
Orbite Aluminae Pan American Goldfields
Nordion Paladin Labs
Dalradian Resources Patheon
Exact Sciences MethylGene
OPMEDIC Group Torex Gold
See more

Latest research

Aberdeen Private Equity Fund

Termination of coverage

Update | Investment Companies | 18/04/2018

Edison Investment Research is terminating coverage on Aberdeen Private Equity Fund (APEF). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Miton Global Opportunities

Termination of coverage

Update | Investment Companies | 18/04/2018

Edison Investment Research is terminating coverage on Miton Global Opportunities (MIGO). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.

Foresight Autonomous Holdings

Time to shine

Update | Technology | 17/04/2018

Foresight (FRSX) is an innovator in automotive vision and cellular V2X accident prevention systems. In Q118, the group launched its QuadSight demo system at CES. It expects to have a prototype by mid-2018 and to launch live demonstrations, which should lead to pilot trials later this year. Also launched in Q118 and about to be spun into its own subsidiary, FRSX’s mobile phone-based Eye-Net solution further extends the safety theme, with real-time collision alerts to pedestrians and drivers.…

Sierra Oncology

Progress with ongoing trials and future plans

Update | Pharmaceutical & healthcare | 16/04/2018

Sierra Oncology held an investor meeting on 27 February 2018, which provided a comprehensive update on its programs. The most immediately impactful data was a favourable safety profile reported from the ongoing Phase I/II clinical trials (monotherapy and gemcitabine combination). It was announced that the monotherapy trial had entered the Phase II dose-expansion portion of the trial and that the combination study will enter this phase in Q218. Preliminary results for this trial are expected in Q418.

BlackRock Greater Europe Investment Trust

Improved performance under new co-manager

Review | Investment Companies | 11/04/2018

BlackRock Greater Europe Investment Trust (BRGE) is co-managed by Stefan Gries (appointed on 20 June 2017), who focuses on developed European markets, and Sam Vecht, who focuses on emerging Europe. They aim to generate long-term capital growth from a relatively concentrated portfolio of 35-40 European equities, mostly from developed markets. BRGE’s investment performance has improved following Gries’ appointment, since when the trust has outperformed the FTSE World Europe ex-UK reference…

Edison North America

Edison’s North American office opened in 2011 to provide research services to companies listed on North American stock exchanges. Companies of all sizes benefit from our research service, which provides the highest standards of equity research and unrivalled distribution of our reports on a global and unrestricted basis.